Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Ali S. Abdelhameed"'
Publikováno v:
Frontiers in Chemistry, Vol 12 (2024)
IntroductionCEP-37440 was synthesized and supplied by the research and development division of Teva Branded Pharmaceutical Products (West Chester, PA, United States). CEP-37440 represents a newly developed compound that exhibits selectivity inhibitio
Externí odkaz:
https://doaj.org/article/cd01d3edd1a645ceb6ac529f55df8c0d
Publikováno v:
Heliyon, Vol 10, Iss 13, Pp e34109- (2024)
The orally given, irreversible, third-generation inhibitor of the epidermal growth factor receptor (EGFR), known as Nazartinib (EGF816), is now undergoing investigation in Phase II clinical trials conducted by Novartis for Non-Small Cell Lung Cancer.
Externí odkaz:
https://doaj.org/article/56f5988244bd42ee8890c17a42fd862a
Publikováno v:
Medicina, Vol 60, Iss 10, p 1626 (2024)
Background and Objectives: Dovitinib (DVB) is a pan-tyrosine kinase inhibitor (TKI) that can be administered orally. In September 2023, the FDA granted Oncoheroes approval to proceed with an Investigational New Drug (IND) application for dovitinib. T
Externí odkaz:
https://doaj.org/article/e33f9546b2814ddaaac014e4801e403e
Autor:
Livia Interdonato, Ylenia Marino, Daniela Impellizzeri, Ramona D’Amico, Rosalba Siracusa, Roberta Fusco, Gaetano Cammilleri, Licia Pantano, Sergio Modafferi, Ali S. Abdelhameed, Tilman Fritsch, Luay J. Rashan, Salvatore Cuzzocrea, Vittorio Calabrese, Marika Cordaro, Rosanna Di Paola
Publikováno v:
Frontiers in Physiology, Vol 14 (2024)
Traumatic brain injury (TBI) is described as a structural damage or physiological disturbance of brain function that occurs after trauma and causes disability or death in people of all ages. New treatment targets for TBI are being explored because cu
Externí odkaz:
https://doaj.org/article/d180bcf4a0e74357a035b67a05f19184
Autor:
Naomi Osakabe, Sergio Modafferi, Maria Laura Ontario, Francesco Rampulla, Vincenzo Zimbone, Maria Rita Migliore, Tilman Fritsch, Ali S. Abdelhameed, Luigi Maiolino, Gabriella Lupo, Carmelina Daniela Anfuso, Elisabetta Genovese, Daniele Monzani, Uwe Wenzel, Edward J. Calabrese, R. Martin Vabulas, Vittorio Calabrese
Publikováno v:
Medicina, Vol 59, Iss 11, p 2045 (2023)
There is substantial experimental and clinical interest in providing effective ways to both prevent and slow the onset of hearing loss. Auditory hair cells, which occur along the basilar membrane of the cochlea, often lose functionality due to age-re
Externí odkaz:
https://doaj.org/article/5fa2a97c277b4196b482acec48382e8b
Publikováno v:
Molecules, Vol 28, Iss 20, p 7220 (2023)
Acalabrutinib, commercially known as Calquence®, is a pharmacological molecule that has robust inhibitory activity against Bruton tyrosine kinase. The medicine in question was carefully developed by the esteemed pharmaceutical company AstraZeneca. T
Externí odkaz:
https://doaj.org/article/0072e95fe11c41e18af14f610163635b
Publikováno v:
Separations, Vol 10, Iss 9, p 472 (2023)
Ribociclib (Kisqali®) is a pharmacological agent that has great selectivity as a cyclin-dependent kinase 4/6 inhibitor. It has received regulatory approval for its application in the treatment of breast cancer. The objective of the current study was
Externí odkaz:
https://doaj.org/article/e03104a05f294d8cbfa5854aeca2747e
Publikováno v:
Separations, Vol 10, Iss 8, p 450 (2023)
Savolitinib (Orpathys®), was developed by (HUTCHMED (Shanghai, China) and, AstraZeneca (Gaithersburg, Maryland, USA), is an inhibitor of the c-Met receptor tyrosine kinase that is orally bioavailable. It was designed for the treatment of pillary and
Externí odkaz:
https://doaj.org/article/e6d4fec8c02e46f6a431998fe1084190
Publikováno v:
Molecules, Vol 28, Iss 10, p 4225 (2023)
Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the management of B-cell tumors and autoimmune disorders. Elementary in-silico studies were first performed to predict sus
Externí odkaz:
https://doaj.org/article/89e56f63b2aa4f13b9ab39b31de340e9
Publikováno v:
Separations, Vol 10, Iss 5, p 302 (2023)
Fenebrutinib (GDC-0853; FNB) is an oral small molecule that was developed by Roche Pharmaceuticals to slow multiple sclerosis progression. FNB is a reversible bruton tyrosine kinase (BTK) inhibitor, which showed the maximum potency of BTK inhibitors
Externí odkaz:
https://doaj.org/article/dd2c40c014ef4924a81d02bde02f59ea